Published in Open Cardiovasc Med J on November 26, 2010
Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med (2012) 1.12
The relationship between the activates of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects. J Diabetes Metab Disord (2012) 0.92
Advanced glycation end-products: modifiable environmental factors profoundly mediate insulin resistance. J Clin Biochem Nutr (2015) 0.87
Exercise Training Prevents Coronary Endothelial Dysfunction in Type 2 Diabetic Mice. Am J Biomed Sci (2011) 0.84
Antioxidants and diabetes. Indian J Endocrinol Metab (2012) 0.80
Hyperglycemia / hypoglycemia-induced mitochondrial dysfunction and cerebral ischemic damage in diabetics. Metab Brain Dis (2014) 0.79
Carbonyl stress in aging process: role of vitamins and phytochemicals as redox regulators. Aging Dis (2013) 0.78
Role of Vitamin D on glycemic control and oxidative stress in type 2 diabetes mellitus. J Res Med Sci (2017) 0.75
Quercetin Isolated from Toona sinensis Leaves Attenuates Hyperglycemia and Protects Hepatocytes in High-Carbohydrate/High-Fat Diet and Alloxan Induced Experimental Diabetic Mice. J Diabetes Res (2016) 0.75
Insights into the development and treatment of cardiovascular disease: a role for animal models. Open Cardiovasc Med J (2010) 0.75
Ginsenoside Rb1 relieves glucose fluctuation-induced oxidative stress and apoptosis in Schwann cells. Neural Regen Res (2012) 0.75
Hydrogen-rich saline prevents bone loss in diabetic rats induced by streptozotocin. Int Orthop (2017) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med (1997) 7.65
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol (2003) 6.78
Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev (2002) 6.05
Oxidative stress and diabetic vascular complications. Diabetes Care (1996) 5.97
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res (1987) 4.42
Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol (2004) 4.10
Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation (2002) 3.71
Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res (1977) 3.70
alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med (1995) 3.58
Endothelial dysfunction in diabetes. Br J Pharmacol (2000) 3.13
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest (2000) 2.89
Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol (2005) 2.88
Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation (2003) 2.69
Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J (1992) 2.68
Biosynthesis of endothelium-derived relaxing factor: a cytosolic enzyme in porcine aortic endothelial cells Ca2+-dependently converts L-arginine into an activator of soluble guanylyl cyclase. Biochem Biophys Res Commun (1989) 2.25
Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr (2009) 2.04
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res (2007) 2.00
Hypertension, angiotensin II, and oxidative stress. N Engl J Med (2002) 1.92
Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag (2007) 1.88
Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol (1986) 1.87
Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care (1997) 1.84
Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res (2009) 1.82
Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care (2003) 1.82
Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol (2008) 1.73
Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol (1992) 1.68
Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem (2009) 1.66
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med (2004) 1.65
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia (1995) 1.63
Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium (2004) 1.62
Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today (2006) 1.59
Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp Gerontol (2009) 1.59
Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J (1975) 1.56
Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ Res (1999) 1.56
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care (1999) 1.46
Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol (2008) 1.45
Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res (2002) 1.42
The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care (2003) 1.42
Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension (1998) 1.42
Endothelial function in the time of the giants. J Cardiovasc Pharmacol (2008) 1.41
Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res (2004) 1.40
Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats. J Nutr Biochem (2003) 1.39
Oxidative stress in diabetes. Clin Chem Lab Med (2003) 1.38
Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia (1999) 1.37
Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul Pharmacol (2006) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism (1995) 1.34
Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol (1988) 1.33
The molecule of the year. Science (1992) 1.32
Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A (2006) 1.32
Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care (2006) 1.31
The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag (2008) 1.30
Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab (2003) 1.29
Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal (2009) 1.28
The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes (2001) 1.26
A contrasting effect of the diabetic state upon the contractile responses of aortic preparations from the rat and rabbit. Br J Pharmacol (1987) 1.25
Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol (1991) 1.23
Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol (2009) 1.22
The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis (1995) 1.21
Diabetes mellitus and coronary heart disease. Am J Kidney Dis (1998) 1.21
Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis (1998) 1.21
EDHF: new therapeutic targets? Pharmacol Res (2004) 1.21
Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol (2003) 1.20
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res (1999) 1.19
Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 1.18
Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-dependent refilling of Ca2+ stores. Circ Res (1999) 1.18
Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol (2001) 1.17
The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease. Bratisl Lek Listy (2000) 1.13
Insulin reversal of diabetes-induced inhibition of vascular contractility in the rat. Am J Physiol (1982) 1.13
Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol (1988) 1.13
Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther (1993) 1.12
Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol (2006) 1.12
Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag (2005) 1.10
Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br J Pharmacol (1992) 1.10
Antioxidants and lipid peroxidation status in diabetic patients with and without complications. Arch Iran Med (2009) 1.08
Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care (2009) 1.08
Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract (2002) 1.08
Influence of the endothelium on contractile responses of arteries from diabetic rats. Eur J Pharmacol (1988) 1.07
Myocardial performance in conscious streptozotocin diabetic rats. Cardiovasc Diabetol (2006) 1.06
Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol (2004) 1.06
Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol (1995) 1.04
Effects of experimental diabetes on the responsiveness of rat aorta. Br J Pharmacol (1989) 1.01
Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diabetes Nutr Metab (2000) 0.99
Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia (2004) 0.99
Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circ J (2006) 0.98
Bioassay of endothelium-derived relaxing factor in diabetic rat aorta. Am J Physiol (1992) 0.97
Hydrogen peroxide-induced endothelium-dependent relaxation of rat aorta involvement of Ca2+ and other cellular metabolites. Gen Pharmacol (1999) 0.97
Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol (1998) 0.97
Time course of changes in endothelium-dependent and -independent relaxation of chronically diabetic aorta: role of reactive oxygen species. Eur J Pharmacol (2000) 0.96
Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation. Pharmacol Rep (2009) 0.96
Human diabetes is associated with hyperreactivity of vascular smooth muscle cells due to altered subcellular Ca2+ distribution. Diabetes (1999) 0.96